secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001549595-24-000038
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment to resume
--------------------------------------------------------------------------------

- FDA cleared new chirally controlled NX-2127 drug product; partial hold lifted March 11, 2024.
- Enrollment reinitiated in Phase 1a/1b for relapsed/refractory B-cell malignancies.
- Prioritizing aggressive NHL (DLBCL, MCL) where durable complete responses previously observed.
- Patients currently enrolled and deriving benefit from prior process may continue treatment.
- Company cites accelerated interest from ASH data and Science publication on BTK degrader programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000038/0001549595-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000038/nrix-20240311.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer